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Available online 5 July 2019Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration
and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify
molecules to prevent OA by regulating chondrocyte senescence and autophagy.
Methods: Human chondrocytes with IL-6 induced senescence and autophagy suppression and SA-β-gal as a re-
porter of senescence and LC3 as reporter of autophagic flux were used to screen the Prestwick Chemical Library
of approved drugs. Preclinical cellular, tissue and blood fromOAand blood fromOAand ageingmodelswere used
to test the efficacy and relevance of activating PPARα related to cartilage degeneration.
Findings: Senotherapeutic molecules with pro-autophagic activity were identified. Fenofibrate (FN), a PPARα ag-
onist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autoph-
agic flux, and protected against cartilage degradation. FN reduced both senescence and inflammation and
increased autophagy in both ageing human and OA chondrocytes whereas PPARα knockdown conferred the op-
posite effect. Moreover, PPARα expression was reduced through both ageing and OA in mice and also in blood
and cartilage from knees of OA patients. Remarkably, in a retrospective study, fibrate treatment improved OA
clinical conditions in human patients from the Osteoarthritis Initiative (OAI) Cohort.
Interpretation: These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect
against cartilage degeneration seenwith ageing and OA. Thus, these drugs could have immediate clinically utility
for age-related cartilage degeneration and OA treatment.
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Increasing evidence about themolecularmechanisms of ageing sug-
gests that many chronic diseases such as osteoarthritis (OA) are associ-
ated with the hallmarks of ageing, including cellular senescence and
defective autophagy [1]. OA is the most prevalent joint disease, and
has a major impact on global health impact in the ageing population,
but neither preventive measures nor disease-modifying treatments
are yet available [2].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Ageing is amajor risk factor in patientswith cartilage degeneration
and Osteoarthritis (OA). Selective targeting of senescent
chondrocytes provides beneficial effects by attenuating inflamma-
tion and enhancing structural support of articular cartilage. Small
molecules capable of eliminating chondrocytes with senescence
features might prevent cartilage dysfunction related to ageing.
Added value of this study
In this study, we screened for compounds that both decrease se-
nescence and increase autophagy by a cell-based high-
throughput screening (HTS) in human chondrocytes. Importantly,
we have identified Fenofibrate, a PPARα agonist targeting lipid
metabolism, as a potential treatment against cartilage ageing
and OA. OA patients treatedwith fibrates have improved physical
functions and therefore better mobility (human cohort study).
Implications of all the available evidence
This study provides novel evidence that activating PPARα by
fibrates prevent cartilage degradation by modulating key mecha-
nisms such as senescence and autophagy in chondrocytes and
cartilage. Collectively, our data establish that fibrates could be
translated into disease-modifying therapeutics for OA patients.
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diseases [3–7]. Articular cartilage of patients with OA shows features of
senescence, including increased expression of nitric oxide, pro-
inflammatory cytokines, particularly IL-1β [8]; p16 [9]; activated
DNA damage response; ROS secretion and SA-β-Gal activity [10].
Senescence-associated secretory phenotype (SASP) factors released
from chondrocytes, such as pro-inflammatory cytokines and extracellu-
lar matrix degrading enzymes, have been identified as major mediators
contributing to the development and progression of OA [11,12]. Simi-
larly, intra-articular injection of senescent cells in mice results in
OA-like pathology [13]. Cartilage ageing can be modified by selective
elimination of senescent chondrocytes to prevent the detrimental mi-
croenvironment changes occurring in joint dysfunction. A major step
into the translation of senolytic treatments for OA was demonstrated
by the beneficial effects of selective clearance of senescence
chondrocytes using the Bcl-2 family inhibitor Navitoclax in animal
models [14]. Physical activity intervention in rats ameliorates the dele-
terious effects of chondrocyte senescence and ageing [15], indicating
that cartilage degeneration responds to environmental signals. The
broad impact of senolytic treatment is also highlighted by the efficacy
of dasatinib and quercetin combination in several models of age-
related disease, which results in an extension of healthspan and lifespan
in mice [6], as well as protects from idiopathic fibrosis in a first-in-
human trial [16]. Comprehensive reviews have highlighted the rele-
vance of senescence in disease and in particular for pathogenesis of
OA [17–20].
There is strong evidence linking deficient autophagy, essential for
cellular homeostasis, with cartilage ageing and OA [21,22]. Given its
broad clinical implications and is relevance in the pathogenesis of dis-
ease, autophagy has become a major target for drug discovery and de-
velopment [23,24]. Autophagy modulation by different means is a
promising therapeutic approach and the discussion is currently focused
on which indication will become the first clinically approved [25]. In-
deed, pharmacological activation of autophagy with small moleculeshas shown efficacy in preclinical models of OA [20]. Activating FoxO
transcription factors protect against OA-associated cartilage damage
[26]. However, targeting these homeostasis mechanisms to identify
and test efficacy of potential disease-modifying treatments for cartilage
ageing and OA has been proven to be challenging.
Cellular senescence and autophagy are not only essential for homeo-
stasis but are potential therapeutic targets for age-related diseases [27].
We aim to test this therapeutic hypothesis in preclinical models of OA,
where senescence and autophagy play a relevant role. A novel cell-
based dual imaging screening assay was developed to identify both
senotherapeutics, able to either suppress markers of senescence
(senomorphics) or to induce apoptosis of senescent cells (senolytics),
and autophagy modulators. Senescence was induced in the T/C28a2
human chondrocyte cell line by IL-6 treatment and the percentage of
cells positive for senescence-associated β-galactosidase (SA-β-Gal) ac-
tivity was quantitated using the C12FDG fluorescence substrate as a re-
porter [28]. The Prestwick chemical library of 1120 off-patent drugs,
combining high chemical and pharmacological diversity with demon-
strated bioavailability and safety in humans was used to screen for se-
nescence modulators. These were subsequently tested for autophagic
flux activity in stably transfected chondrocytes using a LC3 reporter
[29–31]. Among the identified compounds and mechanisms, we se-
lected fenofibrate (FN), a peroxisome proliferator-activated receptor
alpha (PPARα) agonist, that is in clinical use for the treatment of lipid
metabolismdysfunction for further studies [32]. Our data provides com-
pelling evidence that activating PPARα initiates a transcriptional pro-
gram that enhances chondrocyte homeostasis. Moreover, FN and other
ligands were able to prevent cartilage degradation and to positively
modulate key molecular mechanisms such as senescence and autoph-
agy in chondrocytes and cartilage.We also demonstrate that PPARα ex-
pression inmicewas reduced due to ageing or OA and also in blood and
cartilage from knees of OA patients. Collectively, our data establish
strong preclinical evidence that could lead to the development of
novel disease-modifying therapies targeting lipid metabolism to pre-
vent and treat OA.
2. Materials and methods
2.1. Chemicals and materials
Dulbecco's Modified Eagle's Medium (DMEM, Lonza, Basel,
Switzerland, cat# BE-604F), Eagle's Minimum Essential Medium
(EMEM, ATCC®, cat# 30–2003), Fetal Calf Serum (FCS, Gibco by Life
Technologies, CA, cat# 26010–074), FBS (Sigma-Aldrich, St. Louis, MO,
cat# F9665), Penicillin-Streptomycin (P/S, Sigma-Aldrich, cat# P0781),
Puromycin (Sigma-Aldrich, cat# P8833), Glutamax (Thermo Fisher Sci-
entific, CA, cat# 35050–061), Sodium pyruvate solution (Sigma-Aldrich,
cat# S8636), MEM Non-essential Amino Acid Solution (Sigma-Aldrich,
cat# M7145), pBABE-puro mCherry-EGFP-LC3B (Addgene, Cambridge,
MA, cat# 22418, RRID:Addgene_22418), FuGene (Promega, Spain,
cat# E2691), Opti-MEM® (1×) (Thermo Fisher Scientific, cat# 11058),
Hank's Balanced Salt Solution (HBSS, Sigma-Aldrich, cat# H6648),
ImaGene Green™ C12FDG LacZ Gene Expression kit (Life Technologies,
USA, cat# D2893), Hoechst 33342 (Thermo Fisher Scientific, cat#
62249), Paraformaldehyde (PFA, Sigma-Aldrich, cat# 158127), Annexin
V-FITC Apoptosis Detection kit (Inmunostep, Spain, cat# ANXVKF-
100 T), Griess Reagent (Enzo Life Sciences, Ann Arbor, MI, cat# alx-
400-004-L050), Luminata™ Classico Western HRP Substrate, Millipore
Corporation, MA, USA, Cat# WBLUC0100), Pierce® BCA Protein Assay
(Thermo Fisher Scientific, cat# 23225), RNA isolation [Trizol (Thermo
Fisher Scientific, cat# 15596026), RiboPure RNA Purification kit blood
(Thermo Fisher Scientific, cat# AM1928), NZY First-Strand cDNA Syn-
thesis kit (NZYTech, Portugal, cat# MB12501), iScript cDNA Synthesis
kit (Bio-Rad, CA, cat# 1708890)], ImmPRESS DAB Reagent (Vector
Labs, Burlingame, CA cat# MP-7401, RRID:AB_2336529), DAB-
Peroxidase substrate Kit (Vector Labs, cat# SK-4100, RRID:AB_
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France), Fenofibrate (Sigma-Aldrich, MO, cat# F6020, https://www.
drugbank.ca/drugs/DB01039), GW7647 (Sigma-Aldrich, St. Louis, MO,
cat# G6793, https://pubchem.ncbi.nlm.nih.gov/compound/3392731),
CP775146 (Sigma-Aldrich, cat# PZ0173, https://pubchem.ncbi.nlm.
nih.gov/compound/10410059), Rapamycin (Calbiochem, Germany,
cat# 5053210, https://www.drugbank.ca/drugs/DB00877), Navitoclax
(ChemieTek, IN, USA, cat# CT-A263, https://www.drugbank.ca/drugs/
DB12340), Etoposide (Sigma, cat# E1383, https://www.drugbank.ca/
drugs/DB00773), Cloroquine (CQ, Sigma-Aldrich, cat# C6628),
Bafilomycin (Sigma-Aldrich, cat# B1793), Interleukin-6 (IL-6, Sigma-
Aldrich, cat# SRP3096), Interleukin-1β (IL-1β, Sigma-Aldrich, cat#
I9401), Tumor Necrosis Factor α (TNFα, Sigma-Aldrich, cat# T6674),
Actinomycin D (Sigma-Aldrich, cat# A9415), p21 (Cell Signalling Tech-
nology, Netherlands, cat# 2947, RRID:AB_823586), p16 (Abcam, UK,
cat# ab51243, RRID:AB_2059963), phospho-S6 Ribosomal Protein
(prpS6, Cell Signalling Technology, cat# 4858, RRID:AB_916156), LC3
(Cell Signalling Technology, cat# 3868, RRID:AB_2137707), NFκB (Cell
Signalling Technology, cat# 8242, RRID:AB_10859369), PPARα
(Thermo Fisher Scientific, cat# PA1-822A, RRID:AB_2165595), α-
tubulin (Sigma-Aldrich, cat# T9026, RRID:AB_477593), Horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG (Sigma-Aldrich, cat#
NA934, RRID:AB_2722659), Horseradish peroxidase (HRP)-conjugated
anti-mouse IgG (Sigma-Aldrich, cat# NA931, RRID:AB_772210),
Taqman probes (Hs00797944s1 MAP1LC3 FAM, cat# 4331182,
Hs00231106 m1 FOXO1 FAM, cat# 4331182, Hs00355782 m1
CDKN1A FAM, cat# 4331182, Hs05332856 s1 NFκB FAM, cat#
4351372, Hs00912671 m1 CPT1A FAM, Hs01074241 m1 ACOX1 FAM,
CA, cat# 4331182, Hs00947536 m1 PPARα FAM, CA, cat# 4331182,
Thermo Fisher Scientific), h36B4_592F 5´CCACGCTGCTGAACATGC3´,
h36B4_658R 5´TCGAACACCTGCTGGATGAC3, Integrated DNA Technolo-
gies, IDT, CA, cat# 76583076 and cat# 76583077) and h36B4_VIC VIC-
AACATCTCCCCCTTCTCCTTTGGGCT-TAMRA probe (Thermo Fisher Sci-
entific, cat# 450024), siRNA PPARα (ID: 5439, cat# AM51331; Ambion,
Austin, TX, USA), Lipofectamine RNAiMAX transfection reagent (Life
Technologies, NY, USA, cat# 13778030), Silencer Cy-labelled negative
Ctrl N.1 siRNA (Ambion, cat# AM4621), Echo®550 Acoustic Liquid Dis-
pensing Technology (Labcyte, San José, CA), Janus (Perkin Elmer, USA),
Multidrop™Combi Reagent Dispenser (Thermo Fisher Scientific, CA),
Microplate Washer (Biotek, CA), Operetta High-Content Imaging Sys-
tem (Perkin Elmer, USA), Harmony® Image Analysis Software (Perkin
Elmer), FACScalibur cytometer (Becton Dickinson, CA, RRID:SCR_
000401), software CellQuestPro (Becton Dickinson), Amersham Imager
600 (GEHealthcare,Weltham,MA), Image J software (National Institute
of Health, USA, RRID:SCR_003070), Nanoquant Infinite M200 (Tecan,
Switzerland), NanoDrop ND-1000 (Thermo Fisher Scientific, RRID:
SCR_016517), Thermal Cycler (Thermo Fisher Scientific), LightCycler
480 Instrument II (Roche Life Science), qBASE+ qPCR analysis software
(Biogazelle, Switzerland, RRID:SCR_003370), Prism 6.0 software
(GraphPad Software, La Jolla, CA, USA, RRID:SCR_002798).
2.2. T/C28a2 chondrocytes
The immortalized human juvenile chondrocyte cell line T/C28a2
[33], was cultured in DMEM supplemented with 10% FCS and
100 IU/ml Penicillin / 100 μg/ml Streptomycin at 37 °C and 5% CO2.
2.3. Chondrocyte isolation and culture
OAhuman cartilagewas obtained frompatients undergoing knee re-
placement (mean ± SD: 76.8 ± 4.71 years old, n = 5). Normal-Ageing
human cartilage was harvested at the time of autopsy from the femoral
condyles and the tibia plateaus of patients who had no history of joint
disease (mean ± SD: 76.1 ± 14.50 years old, n = 10). Cartilage slices
were minced and incubated with trypsin (0.5 mg/ml) (Sigma-Aldrich,
St. Louis, MO, USA) for 10 min at 37 °C, and then shaken overnight atat 37 °C with collagenase IV (Sigma-Aldrich) in DMEM with 5% FCS.
The digest was centrifuged and the cells were incubated in DMEM
with 10% FCS at 37 °C and 5% CO2. Only first passage cells were used
in the experiments.
2.4. Cartilage explants
Cartilage explants from human normal ageing patients (mean± SD:
73.33 ± 17.95 years old, n = 3) were employed to evaluate cartilage
degradation in response to IL-1β.
2.5. Samples consent statement
The samples needed to carry out this study were obtained from the
collection of samples for the investigation of Rheumatic Diseases of Dr.
Francisco J. Blanco García, from Xerencia de Xestion Integrada de A
Coruña (XXIAC) and Instituto de Investigación Biomédica de A Coruña
(INIBIC). This collection was registered in the National Registry of
Biobanks, with registration code: C.0000424 and approved by the Ethics
Committee of Galicia with registration code: 2013/107. The information
and informed consent sheetwas given to all participants in the research,
whose biological samples and clinical data may be susceptible to be
used in this study and are authorized by the Ethics Committee of Galicia,
Law 14/2007, of the July 3, and Biomedical Research 1716/2011 of No-
vember 18. All the information obtained from the analysis of the sam-
ples will be treated at all times under the criteria of confidentiality
and in accordancewith the security requirements required by the Span-
ish legislation on data protection.
In addition, all methods were performed in accordance with the rel-
evant guidelines and regulations and The Ethics Committee of Galicia,
Spain approved this study.
2.6. Blood from the Spanish OA Cohort PROCOAC (PROspective Cohort of
Osteoarthritis of A Coruña)
Total RNA was extracted from blood from Non-OA patients (Age:
mean ± SD: 60.95 ± 6.51 years old, Body Mass Index (BMI): mean ±
SD: 24.96 ± 3.34, Grade KL 0, Females, n = 25) and knee OA patients
(mean ± SD: 67.42 ± 6.45 years old, BMI: mean ± SD: 29.30 ± 2.83,
Grade KL 3 and 4, Females, n = 30) from the Spanish Cohort
PROCOAC [34].
2.7. Prestwick chemical library
Prestwick chemical library was purchased from Prestwick Chemical.
This collection contains 1120 pharmacological active compounds, 100%
approved drugs (FDA, EMA and other agencies) selected by a team of
medicinal chemists and pharmacists for their high chemical and phar-
macological diversity as well as for their known bioavailability and
safety in humans. The compounds were pre-dissolved at 10 mM con-
centration in DMSO.
2.8. Senescence-associated β-galactosidase activity screening
A Multidrop Combi Reagent Dispenser was used for seeding cells
into 384-well plates (3000 cells/well; Cell Carrier, Perkin Elmer) in
DMEM supplemented with 10% FCS and 1% P/S and cells were cultured
until confluence. Then cells were treated in DMEM 2% FCS with IL-6
20 ng/ml or with Prestwick chemical library at 10 μM. Echo®550 Acous-
tic Liquid Dispensing Technology was used to add 75 nl of each sample
to the interval plate. An automated workstation JANUS and liquid han-
dling was employed to transfer 50 μl per well of IL-6 with the com-
pounds from the interval plate to the assay plate. The final assay
volume was 50 μl. To measure senescence-associated-β-galactosidase
(SA-β-Gal) activity in live cells, we employed ImaGene Green™
C12FDG lacZ Gene Expression Kit (C12FDG) according to the supplier's
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μM) and Hoechst 33342 (2.5 μl/ml) for 1 h at 37 °C and 5% CO2. SA-β-
Gal activity was stopped with phenylethyl β-d-thiogalactoside (PETG,
1 mM) for 5 min at room temperature (RT) and cells were fixed with
PFA 4% for 10 min at RT. CQ (200 μM) was employed as a negative con-
trol for SA-β-Gal activity. For data acquisition, images were captured by
using the Operetta® High Content Screening system. This system is an
automated microscope, which allows automated image adquisition
and analysis. Each well was divided in four stacks with a working dis-
tance of 0.2 μm. The first height was 7.6 μm and the last height was
8.2 μm. We selected three channels for analysis: Brightfield, Hoechst
and Fluorescein. The images were captured using a 20× objective, long
WD. Hoechst allows to identify cell nuclei (excitation = 360–400 nm,
emission = 410–480 nm, exposure time = 100 ms) and Fluorescein
to identify SA-β-Gal activity (excitation = 460–490 nm, emission =
500–550 nm, exposure time= 1800 ms). Brightfield images were cap-
tured by using exposure time = 20 ms.
2.9. Data analysis for chondrocyte senescence
SA-β-Gal data from the screening assay was analysed by using
Harmony® Image Analysis Software. We calculated the average inten-
sity of cytoplasmic fluorescein and number of nuclei in test samples,
as well as in positive and negative controls. Then, we determined a
threshold to define themaximumof senescence. For this, we subtracted
twice the standard deviation from the intensity of cytoplasmic fluores-
cein was substracted two values from the standard deviation (mean –
2SD).We use themean - 2SD value to select compounds from the Prest-
wick chemical library. We determined Z'factor, coefficient of variation
(CV) values and signal-to-background (s/b) ratio for each plate [35].
Screening assay plate datawas considered acceptable if Z´ ≥ 0.5 (Supple-
mentary Fig. 1).
2.10. Autophagy screen
pBABE-puro mCherry-EGFP-LC3B plasmid was obtained from
Addgene.mCherry-EGFP-LC3 retroviruswasproduced as described pre-
viously [36]. HEK 293-T17 (ATCC®, cat# CRL-11268, RRID:CVCL_1926)
cells were used to facilitate retroviral packaging. We employed FuGene
Transfection Reagent, a nonliposomal mixture of lipids as a plasmid de-
livery method. After confirmation of transfection by microscopy, cells
were sorted. Next, we selected the brightest clones by testing the ex-
pression of mCherry and GFP by flow cytometry. Finally, Operetta was
used to evaluate the autophagic flux of selected clones by imaging. Sta-
ble clones weremaintained in the presence of Puromycin (2.5 μg/ml). A
Multidrop Combi Reagent Dispenser was used for seeding cells into
384-well plates (8000 cells/well) in DMEM media supplemented with
10% FCS, 1% P/S and 2.5 μg/ml Puromycin. Cells were incubated over-
night at 37 °C and 5% CO2. Echo®550 Acoustic Liquid Dispensing Tech-
nology was used to transfer compounds that were positive in the anti-
senescence screen. The controls in this assay included DMEM supple-
mented with 2% FCS, IL-6 (20 ng/ml) and Chloroquine (30 μM). Once
the cells adhered to the well, we removed the medium of the final
plate and an automated JANUS workstation was employed to transfer
50 μl per well from interval plates to assay plates. Plates were incubated
for 16 h at 37 °C in an atmosphere of 5% CO2. After incubation, cells were
fixed with PFA 4% for 10 min at 37 °C, washed with HBSS and then, the
nuclei were stained with Hoechst (2.5 μg/ml) for 10 min at 37 °C. A Mi-
croplateWasher Robot and a Multidrop Combi Reagent Dispenser were
used. We used a high-throughput method for quantifying autophagic
flux. We employed the same HTS platform as in the SA-β-Gal assay.
The images were captured using Operetta. Each well was divided into
four stacks with a working distance of 0.2 μm. The first height was 7.6
μm and the last height was 8.2 μm. Cells were selected using four chan-
nels: Brightfield, Hoechst 33342, Fluorescein (EGFP), RFP (mCherry).The images were captured using a 20× objective, longWD as described
in the senescence screen.2.11. Data analysis of autophagic flux
Screening data were analysed using Harmony software. We calcu-
lated mCherry/EGFP Relative Spot Intensity with Harmony Analysis
software. We obtained the mean and standard deviation of the positive
and negative controls. We determined Z'factor, CV values and s/b (sig-
nal-to-background) ratio for each plate [35]. We use the (mean
+ 2SD) value to select compounds from the Prestwick chemical library.
Screening assay plate datawas considered acceptable if Z´ ≥ 0.5 (Supple-
mentary Fig. 2).2.12. Determination of senotherapeutic activity
Human chondrocytes (T/C28a2) were seeded (1 × 104 cells/well) in
96-well plates cultured for 24 h and then treated with IL-6 (20 ng/ml)
and a PPARα agonists (Fenofibrate, CP775146, GW7647) at the indi-
cated concentrations. Navitoclax (2.5 μM) and Rapamycin (10 μM)
were used because of their senolytic and senomorphic effects, respec-
tively. Following addition of the drugs, cells were incubated for 72 h.
For fluorescence analysis of SA-β-Gal activity, we followed the same
protocol as mentioned in SA-β-Gal Activity Screening. For quantitative
analysis of total cell number (Hoechst staining) and number of senes-
cent cells (C12FDG staining), a laser-based scanning confocal imager
(IN Cell Analyzer 6000, GE Healthcare) was used. An acquisition proto-
col was established using the Acquisition software v4.5, including pa-
rameters such as the plates and wells that were imaged, wavelengths,
and exposure time. The acquired images were analysed using the
Multi Target Analysis Module that allows the creation of various deci-
sion trees and the application of appropriate classification filters to dif-
ferent image stacks. All samples were analysed in duplicate with 3–5
fields per well and mean values and standard deviations being calcu-
lated accordingly.2.13. Assessment of cell death
Annexin V apoptosis detection kit was used according to the manu-
facturer's instructions (Immunostep). Chondrocytes were labelled with
Annexin V and Propidium iodide. For each condition, 10,000 events
were collected and FACSCalibur and CellQuestPro software was used
to analyse the data. Results were represented as percentage of
Annexin-V positive cells and percentage of Propidium iodide positive
cells.2.14. Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR)
Total RNA was extracted from blood of Non-OA and Knee OA pa-
tients using Ribopure RNA purification kit and from human T/C28a2
chondrocytes using TRIZOL reagent. Then, 1.5 μg of RNA was used for
complementary DNA (cDNA) synthesis using iScript cDNA synthesis
kit and NZY First-Strand cDNA Synthesis kit for blood and cells, respec-
tively. qRT-PCRwas performed using Taqman Fast AdvanceMasterMix.
Target gene expression was calculated using the comparative CT
method (ΔΔCT) and normalized to an internal control gene 36B4
(qBASE+ qPCR analysis software). The following Taqman probes were
used: Hs00797944 s1 MAP1LC3 FAM, Hs00231106 m1 FOXO1 FAM,
Hs00355782 m1 CDKN1A FAM, Hs05332856 s1 NFκβ FAM,
Hs00912671 m1 CPT1A FAM, Hs01074241 m1 ACOX1 FAM and
Hs00947536 m1 PPARα FAM.
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Cartilage explants from human normal ageing patients were
employed to evaluate cartilage degradation in response to IL-1β. Serial
sections (4 μm)were cut, stainedwith SafraninO– fast green to evaluate
proteoglycan loss.
2.16. Nitric oxide assay
Griess reaction was used to quantify Nitric oxide (NO) production in
themediumof primary human chondrocytes. An equal volumeof Griess
reagent and cellular supernatant (50:50 μl) were mixed and shaken for
10 min in the dark. Absorbance was measured at 570 nm on a micro-
plate reader (Nanoquant Infinite M200).
2.17. Western blotting
Western blotting was performed with a chemiluminescence detec-
tion system. Cell lysates were obtained from OA and ageing primary
human chondrocytes. Protein Sample preparation andWestern Blotting
was performed as described previously [37]. The membranes were in-
cubated with primary antibodies against p21 (1:1000), p16 (1:1000),
prpS6 (1:2000), LC3 (1:1000), NF-κB p65 (1:1000) and PPARα
(1:1000) at 4 °C overnight.α-Tubulin antibody (1:5000)was incubated
for 1 h at room temperature. Next, themembraneswere incubatedwith
horseradish peroxidase (HRP)-conjugated anti rabbit IgG for 1 h at RT.
Membranes were washed 3 times with TBS-T and protein bands were
detected using a chemiluminescence substrate and a detection system
(Amersham Imager 600). The intensity of the bands was quantified by
using ImageJ software.
2.18. Autophagy inhibition by transfection with PPARα small interference
RNA
T/C28a2 human chondrocytes were transiently transfected with
small interference RNA (siRNA) for PPARα, using Lipofectamine
RNAiMAX transfection reagent according to themanufacturer's instruc-
tions. Silencer Cy-labelled negative Ctrl N.1 siRNA was employed as
control.
2.19. Histological analyses
Human knee cartilage samples from normal ageing donors (n = 3)
were fixed in 10% zinc-buffered formalin for 24 h. Knee joints from 6,
12, 18 and 30-month-old C57BL/6 J mice with spontaneous ageing-
related OA (n= 3 per time point) and from C57BL/6 J mice with OA in-
duced by transection of the medial meniscotibial ligament and the me-
dial collateral ligament (MMTL+MCL) (sham surgery and 10 weeks
after surgery; n = 3) were fixed in 10% zinc-buffered formalin for
24 h and decalcified in TBD-2 for 48 h. Sectionswere stainedwith Safra-
nin O–fast green. Histological scoring of OA-like changes on the medial
femoral condyle and tibial plateau from mice was performed using the
Osteoarthritis Research Society International (OARSI) scoring system
(score range 0 to 6) [38]. Paraffin sections from mouse models were
provided from Dr. Martin Lotz at the Scripps Research, La Jolla, CA, USA.
2.20. Immunohistochemistry
Human cartilage andmouse knee joint sectionswere deparaffinized,
washed, and blocked with 10% goat serum. Primary antibody against
PPARα (1:500) was applied and incubated overnight at 4 °C, followed
by ImmPRESS reagents. The signal was developed with
Diaminobenzidine-Peroxidase substrate Kit. The number of PPARα-
positive cells was quantified.2.21. Quantification of positive chondrocytes in human cartilage andmouse
knee joint sections
In human cartilage, 3 pictures per section were taken under 10×
magnification. In mouse knee joints from spontaneous ageing-related
OA model and surgically induced OA, 3 pictures were taken under 10×
magnification, showing the center of the femoral condyle that is not
covered by the menisci as well as the medial and lateral femoral con-
dyles. Then, the total number of PPARα-positive cells was counted in
each section [39].
2.22. Statistical analysis
To test for normal distribution of the data, we used the Kolmogorov-
Smirnov test. In general, the data sets followed a normal distribution.
Statistically significant differences between 2 groups were determined
by Student's t-test, while differences betweenmultiple groups were de-
termined analyzing variance (ANOVA) in conjunction with Tukey's
multiple comparison. The data analysis and statistical inference was
performed by using Prism 6.0 software. The results are reported as the
mean ± SEM. p values b.05 were considered significant.
2.23. Analysis of knee osteoarthritis patients treated with fibrates from Os-
teoarthritis Initiative (OAI) Cohort
For the present study, we used longitudinal data obtained from the
multicenter, longitudinal, prospective observational study of knee OA,
Osteoarthritis Initiative (OAI). The OAI data are publicly available at
https://oai.nih.gov. Specific datasets used were: “MIF00”, “MIF01”,
“MIF03”, “MIF05” (release versions 0.2.2, 1.2.1, 3.2.1, and 5.2.1, respec-
tively); “AllClinical00”, “AllClinical01”, “AllClinical03”, “AllClinical05”
(release versions 0.2.3, 1.2.2, 3.2.1, and 5.2.1, respectively); “Enrollees00
(release version 25)”; “Outcomes99” (release version 10).
The detailed information about the OAI protocol can be found at the
osteoarthritis initiative protocol for the cohort study, from http://data-
archive.nimh.nih.gov/binaries/content/documents/ndacms/resources/
oai/oai-study protocol/oai-study-protocol/ndacms%3Aresource. The
OAI cohort consists of a progression subcohort (patientswith symptom-
atic tibiofemoral knee OA, n= 1390), an incidence subcohort (subjects
with increased risk of OA, n= 3284) and a reference control subcohort
(n= 122). In this analysis we used the longitudinal data from both the
progression and incidence subcohorts. The main inclusion criteria were
the following: age between 45 and 79 years for both subcohorts, symp-
tomatic tibiofemoral knee OA for the progression subcohort, and the
presence of established or putative risk factors for incident knee OA
for the incidence subcohort. TheOAI participantswere recruited and en-
rolled between February 2004 and May 2006 at four recruitment cen-
tres in the United States. This study was approved by institutional
reviewboard committees fromeach recruitment centre. Before entering
the study, all participants provided written informed consent. The
prespecified sample size was 5000 participants (4000 in the incidence
subcohort, 800 in the progression subcohort). It was expected that
this sample size would provide an adequate number of knees with inci-
dent and worsening OA-related structural and clinical changes in order
to achieve the primary aims of the OAI study.
2.23.1. Clinical measures
Height was measured in millimetres using a calibrated, wall-
mounted stadiometer. The measurement was performed twice with
the subject in light clothing, without shoes, and during inspiration.
Bodyweightwasmeasured in kilogramswith a calibrated, standard bal-
ance beam scale. The measurement was performed twice with the sub-
ject in light clothing without shoes, heavy jewellery or wallets. Body
mass index (BMI) was calculated based on weight (in kg) divided by
height (in cm) squared. Prior knee surgery was evaluated using inter-
view. Self-reported physical activity was measured using the Physical
593U. Nogueira-Recalde et al. / EBioMedicine 45 (2019) 588–605Activity Scale for the Elderly (PASE) [40]. To evaluate the severity of OA
symptoms, the self-reported Western Ontario McMaster Osteoarthritis
Index (WOMAC) (5 point Likert scale) for addressing pain, function,
and stiffness was used [41]. The possible range for pain was 0–20, for
physical function was 0–68, and for stiffness was 0–8. In OAI, WOMAC
subscores are reported separately for each knee. For the analyses, we
used the highest from the left and right sided scores for the WOMACFig. 1. Cell-based imaging screening to identify senescence and autophagymodulators. a. Schem
chondrocytes treated with IL-6 (20 ng/ml) +/− Prestwick Chemical Library (1120 compounds
nuclei staining. Then, chondrocyte senescence was determined with C12FDG to quantify sene
System (HCIS). Secondary screening was performed in an autophagy reporter cell line in
Prestwick Chemical Library (279 compounds, 10 μM) for 18 h in a 384 well plate. Hoechst
chondrocyte senescence at 72 h. Cellular senescence was determined with the Galactosid
inhibitor. Scale bar, 100 μm. SA-β-Gal activity was represented by the intensity of the cytopl
Ctrl, two-tailed unpaired Student's t-test. c. IL-6 (20 ng/ml) reduced autophagic flux at 18 h. Chlo
agic flux was represented by the ratio between mCherry/EGFP. Values are mean ± SEM of 28subcategories. The outcomes were assessed at baseline and annually
until year 3. The WOMAC scores after joint replacement were coded
as missing values.
To acquire information about the use of fibrates, amedication inven-
torymethodwas used. In this method the participants bring in all of the
medications they are currently taking, and the brand name, generic
name or active ingredients are recorded and matched to an entry inatic imaging screening development. Primary screeningwas performed in T/C28a2 human
, 10 μM) for 72 h in a 384 well plate. Hoechst 33342 (1 μM) was employed for 10 min for
scence-associated β-Galactosidase (SA-β-Gal) activity by using a High Content Imaging
human chondrocytes (mCherryEGFPLC3 T/C28a2) treated with IL-6 (20 ng/ml) +/−
33342 (1 μM) was employed for 10 min for nuclei staining b. IL-6 (20 ng/ml) induced
ase susbtrate, C12FDG by HCIS. Chloroquine (CQ, 200 μM) was employed as SA-β-Gal
asm fluorescein. Values are mean ± SEM of 60 well/condition, *p b .0001, **p b .0001 vs.
roquine (CQ, 30 μM)was employed as autophagic flux inhibitor. Scale bar, 50 μm. Autoph-
well/condition, *p b .0001, **p b .0001 vs. Ctrl, two-tailed unpaired Student's t-test.
594 U. Nogueira-Recalde et al. / EBioMedicine 45 (2019) 588–605an online medication dictionary [42]. Fibrate users were defined as
those with at least one recorded use during first three years of the
study, excluding baseline use (a “new-user” design). We considered
participants to be users regardless of consistency of fibrate use and its
duration, thus mimicking intent-to-treat analysis in randomized con-
trolled studies.
2.23.2. Statistical analysis
The genetic matching method was used to match fibrate users with
non-users. Genetic matching is a multivariable matching approach
making the distribution of baseline characteristics in “treatment” and
“control” groups as similar as possible. Genetic matching uses an auto-
mated evolutionary search algorithm to determine the weight each co-
variate is given. This method combines multivariate matching on the
covariates and propensity score-matching that allows to optimizeFig. 2. Identification of senescence and autophagymodulators. a. Primary screeningwas perform
Library 10 μM(1120 compounds) at 72 h. CQ (200 μM) for 30minwas employed as negative co
mean of cytoplasmic fluorescein intensity. 279 compounds were identified as senotherapeutics
screening inmCherryEGFPLC3 T/C28a2 human chondrocytes treatedwith IL-6 (20 ng/ml)+/−
as negative control for autophagic flux. Autophagic flux was determined by the ratio mCherr
Compounds were considered hits bymean + 2SD on average Z'factor of 0.58.covariate balance between matched samples. Compared with other
matchingmethods, genetic matching has been found to improve covar-
iate balance and reduce bias [43]. We used one-to one matching with
replacement as it was shown to lead to less bias [44]. The following po-
tential confounding variables were used for thematching: demographic
characteristics, body mass index, prior knee surgery, baseline outcome
measures, and PASE. After all matches were done, differences between
the two groups were compared by standardized differences, ≥ 0.1 was
defined as meaningful disbalance [45]. After matching was performed,
generalized estimating equations (GEE) were used to model the rela-
tionship between outcomes measured over time and fibrate use. For
the assessment of changes in outcome measures over time, we used
the user*time interaction term. A β-coefficient for this interaction
term indicates yearly change in the outcomeparameter assuming linear
development over time. The GEE models were fitted using robusted in T/C28a2 human chondrocytes treatedwith IL-6 (20 ng/ml)+/− Prestwick Chemical
ntrol of SA-β-Gal activity. SA-β-Gal activity was determined by C12FDG and represented by
. Compounds were considered hits bymean - 2SD on average Z'factor of 0.53. b. Secondary
of Prestwick Chemical Library 10 μM(279 compounds) at 18 h. CQ (30 μM)was employed
y/EGFP. 14 compounds were identified as senotherapeutics and autophagy modulators.
Table 1
Identified compounds with senotherapeutic and pro-autophagy activity.
Compounds β-Gal activity Cell number Autophagic flux Target
Bupivacaine hydrochloride 1142 865 1.60 Sodium ion channels
Minoxidil 1185 950 1.59 Potassium channels
Fenofibrate 1234 997 1.57 Peroxisome Proliferator Receptor α
Pentolinium bitartrate 1162 964 1.59 Unknown
Tomatine 1142 970 1.57 Unknown
Benzydamine hydrochloride 1196 1016 1.57 Cyclooxygenase
Ciproheptadine hydrochloride 1031 914 1.6 Histamine H1 and Serotonin receptors
Lomefloxacin hydrochloride 1155 1046 1.58 DNA replication
Flutamide 1091 995 1.57 Androgen receptor
Digitoxigenin 1382 1262 1.59 Na,K ATPase
Guanethidine sulfate 1101 1030 1.58 Adrenergic system
Antipyrine 997 1046 1.61 Prostaglandin G/H synthase 1 and 2
Astemizole 712 770 1.63 Histamine H1 receptor
Pherphenazine 878 985 1.62 Dopamine D2 receptor
595U. Nogueira-Recalde et al. / EBioMedicine 45 (2019) 588–605standard errors computed by a “sandwich” estimator. An exchangeable
correlation structurewas used to correct for the correlation between re-
peated measurements. Although selection of proper correlation struc-
ture is the assumption in GEE models, the method is robust against
violation of this assumption. GEE allows for not using imputation
methods for the missing data, because the participants with missing
data are not excluded from the analysis [46]. Geneticmatchingwas per-
formed using “Matchit” package for R (version 3.0.2) [47]. GEE analyses
were done with “gee” package for R (version 4.13–19) [48]. All statisti-
cal analyses were performed using R software (version 3.5.1).Fig. 3. Fenofibrate, a PPARα agonist, reduces chondrocyte senescence and induces autophagic fl
combination for 72 h in a 384well plate. CQ (200 μM)was employed as inhibitor of SA-β-Gal act
vs. IL-6, two-tailed unpaired Student's t-test. b.mCherry-EGFPLC3 T/C28a2 human chondrocytes
plate. CQ (200 μM)was employed as inhibitor of autophagicflux. Scale bar, 50 μm.Values areme
t-test.3. Results
3.1. Identification of senescence and autophagy modulators
A cell-based imaging assay in human chondrocytes was used to
identify compounds that modulate senescence and autophagy as
novel OA disease-modifying therapeutics. Chondrocytes were treated
simultaneously with IL-6 and compounds from the Prestwick Chemical
library. To quantify senescence, fluorescent SA-β-Gal activity was
analysed using the C12FDG substrate and the ratio of fluorescent signalux. a. T/C28a2 human chondrocytes were treatedwith IL-6 (20 ng/ml), or FN (10 μM), or in
ivity. Scale bar, 100 μm. Values aremean±SEMof 30well/condition, *p b .0001, **p b .0001
were treatedwith IL-6 (20 ng/ml), or FN (10 μM), or in combination for 18 h in a 384well
an±SEMof 16well/condition, *pb .0001, **p b .0001 vs. IL-6, two-tailed unpaired Student's
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Fig. 5. FN selectively kill senescent chondrocytes through inducing cell death by apoptosis. a. Flow cytometry determination of early apoptosis by Annexin-V staining, and late apoptosis by
propidium iodide (PI) staining in T/C28a2 human chondrocytes treatedwith IL-6 (20 ng/ml), or in combinationwith FN, CP andGW(10, 50 μM), Rapa (10 μM), orwithNavitoclax (2.5 μM)
for 72 h in a 12well plate. b. Quantitative analysis of chondrocyte death by Annexin-V and PI staining in human chondrocytes. Values aremean± SEMof three independent observations.
Early apoptosis: *p b .01, **p b .0001, ***p b .05 vs. IL-6; Late apoptosis: *p b .05, **p b .05, ***p b .01, and ****p b .0001 vs. IL-6, two-tailed unpaired Student's t-test.
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agic flux (Fig. 1a). In this system, IL-6 induced a significant increase in
both the percentage of cells positive for in SA-β-Gal activity at 72 h
(Fig. 1b) and overall SA-β-Gal activity. Similarly, IL-6 induced a signifi-
cant decrease in autophagic flux as well as the percent of cells positive
for autophagy at 18 h (Fig. 1c). Chloroquine (CQ), an intracellular β-
Gal and autophagic flux inhibitor, was employed as a negative control.
In addition, p21, an important senescence marker [49] and phospho-
ribosomal S6 (prbS6), a direct target of the mammalian target of
rapamycin (mTOR) [50], were significantly increased after IL-6 stimula-
tion (Supplementary Fig. 3).
Results showed that 279 compounds from the Prestwick library de-
creased IL-6 induced senescence (Fig. 2a). From this set of 279, 14 com-
pounds also increased autophagic flux and were selected as dual
senescence and autophagy modulators for confirmatory studiesFig. 4. PPARα agonists are senolytics inhuman chondrocytes. a. T/C28a2 human chondrocyte
or Navitoclax (2.5 μM) for 72 h in a 96well plate. Relative senescence cells: values aremean± S
cell number: values aremean±SEMof 4well/condition, *pb 0.05, **p b 0.01 and ***pb 0.01 vs. IL
IL-6 (20 ng/ml) in combination with CP (1,582 – 50 μM), Rapa (10 μM), or Navitoclax (2.5 μM
condition, *p b 0.01, **p b 0.0001 vs. IL-6. Relative cell number: values are mean ± SEM of 4 w
human chondrocytes were treated with IL-6 (20 ng/ml) in combination with GW (1,582
senescence cells: values are mean ± SEM of 4 well/condition, *p b 0.05, **p b 0.001, ***p b 0
condition, *p b 0.05, **p b 0.001 and ***p b 0.05 vs. IL-6, two-tailed unpaired Student’s t-test. d
with FN in response to IL-6 treatment. Scale bar, 100 μm.(Fig. 2b). The compounds identified primarily targeted ion channels
and hormone receptors related to metabolism (Table 1). Peroxisome
proliferator-activated receptor alpha (PPARα), a therapeutic target for
lipidmetabolismdysfunction [32]was considered relevant for chondro-
cyte homeostasis so PPARα modulators were selected for further stud-
ies. Fenofibrate (FN), a PPARα agonist significantly reduced SA-β-Gal
activity in IL-6 treated chondrocytes at 72 h (Fig. 3a) and this was ac-
companied by an increase in autophagic flux at 18 h (Fig. 3b),
confirming its senotherapeutic and autophagy promoting activity.
3.2. PPARα agonists function as senolytics to selectively kill senescent
chondrocytes through cell death by apoptosis
To characterize the senotherapeutic activity of FN and other selec-
tive PPARα agonists, such as CP775146 and GW7647, the agonistsswere treatedwith IL-6 (20 ng/ml) in combinationwith FN (1,582 – 50 μM), Rapa (10 μM),
EM of 4well/condition, *p b 0.05, **p b 0.01, ***p b 0.0001 and ****p b 0.0001 vs. IL-6. Relative
-6, two-tailed unpaired Student’s t-test.b.T/C28a2 human chondrocyteswere treatedwith
) for 72 h in a 96 well plate. Relative senescence cells: values are mean ± SEM of 4 well/
ell/condition *p b 0.01, **p b 0.01 vs. IL-6, two-tailed unpaired Student’s t-test. c. T/C28a2
– 50 μM), Rapa (10 μM), or Navitoclax (2.5 μM) for 72 h in a 96 well plate. Relative
.01 and ****p b 0.0001 vs. IL-6. Relative cell number: values are mean ± SEM of 4 well/
. Representative images of SA-β-Gal activity from T/C28a2 human chondrocytes treated
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for 72 h. The PPARα agonists showed senolytic activity in human
chondrocytes by reducing both the number of senescent cells and
total number of cells. FN showed a dose-dependent senolytic effect
(Fig. 4a), GW7647 was toxic at 50 μM (Fig. 4b) and CP775146 was
senolytic only at 12.5 μM (Fig. 4c). Navitoclax and Rapamycin (Rapa)
were employed as positive control for senolytic and senomorphic activ-
ity, respectively.
To investigate how senescent cells were eliminated by PPARα ago-
nists, chondrocyte death was determined by evaluating early and late
apoptosis, using annexin-V and propidium iodide (PI), respectively
(Fig. 5a). Quantification of apoptosis demonstrated that PPARα agonists
(10 and 50 μM) selectively eliminated senescenct cells by increasing ap-
optosis following IL-6-mediated induction of senescence (Fig. 5b). FN
showed similar effects to navitoclax (a reference control for senolytic
activity), while the senomorphic drug rapamycin did not increase apo-
ptosis. These results suggest that the senolytic activity of FN in human
chondrocytes is associated with selective induction of apoptosis.
Moreover, to evaluate the senolytic effect of PPARα activation, se-
nescent human IMR90 lung fibroblasts and DNA repair deficient
Ercc1−/− MEFs fibroblasts were employed [28,51]. The results showed
that PPARα agonists act as senolytics in bothmodels, indicating the po-
tential senotherapeutic effect of activating lipid metabolism in multiple
senescent cell types (Supplementary Fig. 4 and Supplementary Fig. 5).
3.3. Homeostasis markers are positively regulated by PPARα agonists
Todetermine the effects of PPARαmodulators on cellular homeosta-
sis mechanisms such as autophagy and FoxO signalling pathway,
human chondrocytes were treated with PPARα agonists (10 and 50
μM) following exposure to IL-6. Only FN increased autophagic flux at
both concentrations while the other PPARα agonists showed lower
and mostly non-significant effects. Rapamycin and chloroquine (CQ)
showed the expected effects as positive and negative controls for au-
tophagic flux (Fig. 6a). In addition, PPARα agonists also increased LC3
and FoxO1 gene expression at 8 and 24 h (Fig. 6 b, c). Taken together,
these results demonstrate that FN regulates homeostasis in human
chondrocytes as both a senolytic and autophagymodulating compound
(Fig. 6d).
3.4. FN protects against cartilage degradation and regulates senescence, au-
tophagy and inflammation
Treatment with FN reduced proteoglycan loss in cartilage explants
and protected against cartilage degradation in response to IL-1β treat-
ment (Fig. 7a). This protective role was correlated with a reduction of
nitric oxide (NO) production (Fig. 7b). Moreover, FN treatment did
not induce cell death in primary non-senescent human chondrocytes
(Supplementary Fig. 6).
Human OA and ageing primary chondrocytes were employed to fur-
ther investigate the influence of FN on senescence, autophagy, inflam-
mation and cartilage degradation. The levels of expression of the
senescence markers p21 and p16, the key autophagy regulator LC3
and the p65/RelA subunit of NF-κB, a key regulator of SASP, were eval-
uated as well as the extent of phosphorylation of pS6 as a marker for
mTOR activity. In OA chondrocytes, FN reduced expression of p21 and
the NF-κB p65 subunit RELA (Fig. 7c) and reduced phosphor-S6. InFig. 6. PPARα agonistsmodulate key homeostasis markers in human chondrocytes. a.mCh
combination with PPARα agonists FN, CP and GW (10, 50 μM) for 18 h in a 96 well plate. Rap
respectively. Values are mean ± SEM of 6 independent observations, *p b 0.05, **p b 0.05, *
expression of LC3 in T/C28a2 human chondrocytes untreated or treated with FN, CP and GW
*p b 0.01, **p b 0.0001, ***p b 0.0001 vs. IL-6; 24 h: *p b 0.05, **p b 0.0001 vs. IL-6, two-tailed un
untreated or treated with FN, CP and GW (10, 50 μM) for 8 and 24 h. Values are mean ± SEM
b 0.05, ***p b 0.01 vs. IL-6), two-tailed unpaired Student’s t-test. d. Relative senescence cells: v
values are mean ± SEM of 16 well/condition, *p b 0.05 and ***p b 0.01 vs. IL-6, two-tailed unp
well/condition, *p b 0.0001, **p b 0.0001 vs. IL-6, two-tailed unpaired Student’s t-test.ageing chondrocytes FN, reduced expression of p16, p21 and NFκB/
RELA and increased expression of LC3 while reducing the level of
phospho-S6 (Fig. 7d). This regulation of senescence and autophagy
markers in the chondrocyte cultures is likely conferred through the de-
letion of senescent chondrocytes. Remarkably, genetic deletion of
PPARα promoted senescence and SASP/inflammation by increasing
p21 and NF-κB/RELA expression levels respectively as well as increased
LC3 and reduced FOXO1 expression (Fig. 7e-i). These data are consistent
with FN treatment inducing the selective elimination of senescent cells
and favorably modulating inflammatory and metabolic responses in-
volved in OA pathogenesis.
3.5. FN increases PPARα expression and regulates the β-oxidation tran-
scriptional program in human chondrocytes
PPARα regulates fatty acid (FA) β-oxidation and is involved in regu-
lation of energy homeostasis [52]. PPARα also appears to auto-regulate
its own expression. Thus, we examined if FN regulates PPARα in human
chondrocytes. FN treatment increased PPARα expression at both gene
and protein level (Fig. 8a, b) and that PPARα agonists regulated FA β-
oxidation genes in human chondrocytes (Fig. 8c, d).
3.6. PPARα is downregulated in mouse models of ageing and OA
The expression pattern of PPARα in cartilage with ageing and OA
was investigated in natural ageing and in a surgically-induced OA
model in mice. The number of PPARα-positive chondrocytes in knee
cartilage significantly decreased with ageing, with only a minimal per-
centage of the cells positive for PPARα at 30months (Fig. 9a). In the sur-
gical OA model, 10 weeks after transection of the medial meniscotibial
ligament and the medial collateral ligament (MMTL+MCL), PPARα-
positive cells were also significantly reduced (Fig. 9b).
3.7. PPARα is reduced in OA patients and its pharmacological activation im-
proved their clinical conditions
The relevance and potential translation of this mechanism was ex-
plored by analyzing human cohorts of OA patients. To invEstigate the
role of PPARα as a potential biomarker of OA, blood from the PROspec-
tive Osteoarthritis Cohort of A Coruña (PROCOAC) and human cartilage
from non-OA and knee OA patients were employed. Levels of PPARα
were lower in OA patients compared to non-OA controls (Fig. 10a). In
addition, immunohistochemical analysis of cartilage showed that
PPARαwasmainly expressed in the superficial zone in non-OA cartilage
with decreased expression in OA grade III-VI patients. Moreover, in OA
cartilage, PPARα positive cells were present only in the chondrocyte
clusters (Fig. 10b, c).
The potential efficacy of PPARα agonists was also evaluated using
the Osteoarthritis Initiative (OAI) Cohort. In this cohort, there were 35
fibrate users and 3322 participants not taking fibrates in the selected
sample (Supplementary Fig. 7). Using a genetic matching, 35 fibrate
users were matched to 35 participants in the control group. After
matching, all standardized differences of means decreased to b0.05, in-
dicating that the matched groups had b5% of standard deviation differ-
ence in the corresponding variables. Therefore, it was considered that
covariates were well balanced between groups (Supplementary
Table 1). From the total of 35 fibrate users, twenty-four users (68.6%)erry-EGFPLC3 T/C28a2 human chondrocytes were treated with IL-6 (20 ng/ml) alone or in
a (10 μM) and CQ (30 μM) were employed as activator and inhibitor of autophagic flux,
**p b 0.0001 and ****p b 0.0001 vs. IL-6, two-tailed unpaired Student’s t-test. b. Relative
(10, 50 μM) for 8 and 24 h. Values are mean ± SEM of 3 independent observations (8 h:
paired Student’s t-test). c. Relative expression of FoxO1 in T/C28a2 human chondrocytes
of 3 independent observations (8 h: *p b 0.0001, **p b 0.0001 vs. IL-6, 24 h: *p b 0.05, **p
alues are mean ± SEM of 16 well/condition, ***p b 0.0001 vs. IL-6. Relative cell number:
aired Student’s t-test. e. Determination of autophagic flux. Values are mean ± SEM of 16
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Fig. 8. FN increases PPARα expression and regulates β-oxidation in human chondrocytes. a. Relative expression of PPARα in T/C28a2 human chondrocytes untreated or treated with FN
(10, 50 μM) for 24 h. Values are mean ± SEM of 3 independent observations, *p b .05 vs. Ctrl, two-tailed unpaired Student's t-test. b. Western blot and densitometric analysis of PPARα
expression in human OA primary chondrocytes treated with FN (10, 50 μM) for 24 h. Values are mean ± SEM of 3 human donors, *p b .05 vs. Ctrl, two-tailed unpaired Student's t-test.
α-tubulin was employed as a loading control. c. Relative expression of ACOX1 in T/C28a2 human chondrocytes untreated or treated with PPARα agonists FN, CP and GW (10, 50 μM)
for 8 and 24 h. Values are mean ± SEM of 3 independent observations (8 h: *p b .05 vs. Ctrl, two-tailed unpaired Student's t-test; 24 h: *p b .001 vs. Ctrl, two-tailed unpaired Student's
t-test). d. Relative expression of CPT1A in T/C28a2 human chondrocytes untreated or treated with PPARα agonists FN, CP and GW (10, 50 μM) for 8 and 24 h. Values are mean ± SEM
of 3 independent observations (8 h: *p b .05 vs. Ctrl, two-tailed unpaired Student's t-test; 24 h: *p b .01, **p b 0,01, ***p b .001 vs. Ctrl, two-tailed unpaired Student's t-test).
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and one user was initially taking gemfibrozil and then switched to FN.
Furthermore, during the follow-up there were 3 (4.3% of the knees)
total knee replacements in the fibrate user group and 7 (11.4% of the
knees) in the matched control group, respectively. Interestingly, the re-
sults indicate that fibrate use by time interaction was associated with aFig. 7. FN regulates senescence, autophagy and cartilage degradation in human chondrocytes an
donors treated with FN (10, 50 μM), IL-1β (5 ng/ml) or in combination for 72 h. Scale bar, 10
treated with FN (10, 50 μM), IL-1β (5 ng/ml) or in combination for 24 h. Values are mean ±
Student's t-test. c. Western blot and densitometric analysis of p21, prbS6 and NFκB expression
employed as a loading control. Values are mean ± SEM of n = 3 human donors for p21 and n
test. d. Western blot and densitometric analysis of p16, p21, LC3II, prbS6 and NFκB expression
was employed as a loading control. Values are mean ± SEM of n = 6 human donors for p16
tailed unpaired Student's t-test. e-i, Relative expression of PPARα, p21, LC3, FOXO1 and NFκB, i
± SEM. PPARα: *p b .05, n = 3 independent observations, p21: *p b .05, n = 4 independent ob
*p b .05, n = 4 independent observations vs. Mock, two-tailed unpaired Student's t-test.statistically significant improvement of WOMAC function and WOMAC
total scores. There was also a trend towards a decrease inWOMAC pain
score. The results suggest that the fibrate use, when compared with
non-use, was associated with an average yearly decrease in WOMAC
function grade by 1.15 and WOMAC total score by 1.6, as reflected by
β-coefficients of 1.15 and 1.6, respectively (Fig. 10d).d cartilage. a. Safranin O–stained sections representative of n= 3 human ageing cartilage
μm. b. Nitric oxide (NO) production into supernatants from human ageing chondrocytes
SEM of n = 5 human donors. *p b .05 vs. IL-1β, **p b .05 vs. Ctrl, two-tailed unpaired
in human OA primary chondrocytes treated with FN (10, 50 μM) for 24 h. α-tubulin was
= 4 human donors for prbS6 and NFκβ, *p b .05 vs. Ctrl, two-tailed unpaired Student's t-
in human ageing primary chondrocytes treated with FN (10, 50 μM) for 24 h. α-tubulin
and p21; n = 5 for LC3 and prbS6, *p b .05 vs. Ctrl; n = 4 for NFκB, *p b .01 vs. Ctrl, two-
n T/C28a2 human chondrocytes subjected to genetic deletion of PPARα. Values are mean
servations, LC3: *p b .05, n = 3 independent observations, FOXO1: *p b .01, n = 6, NFκB:
Fig. 9. PPARα is downregulatedwith ageing andOA inmice. a. Knee joint sections fromC57Bl6/J were analysed by immunohistochemistry for PPARα. Representative images of knee joints
from 2, 6, 12, 18 and 30-month-oldmice stainedwith Safranin O-Fast Green and PPARα. Scale bar, 10 μm. b, Quantitative analysis of PPARα-positive cells. Values are themean± SEM of 3
mice per group. *p b .05; **p b .0001 vs. 2-month-old mice, two-tailed unpaired Student's t-test. c, Reduction in PPARα expression in knee joints from mice with surgically induced
osteoarthritis (OA). Knee joints from 6-month-old C57BL/6 J mice that underwent sham surgery and from mice 10 weeks after surgical OA induced by transection of the medial
meniscotibial ligament and the medial collateral ligament (DMM), analysed using Safranin O staining for expression of PPARα. Scale bar, 10 μm. d, Quantification of PPARα-positive
cells. Values are the mean ± SEM of 4 mice per group. *p b .05 vs. Sham, two-tailed unpaired Student's t-test.
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Disease-modifying therapeutic agents to prevent or stopprogression
of OA are an urgent clinical need. Recent data support that selective
targeting of senescent chondrocyteswith smallmolecules is an effective
therapy in preclinical models of OA [14]. Activation of autophagy pre-
vents against chondrocyte death, cartilage ageing and OA [21,22]. We
hypothesized that simultaneously targeting senescence and autophagy
in chondrocytes might be a useful strategy to identify therapeutic
agents for joint ageing and OA. Here, we have identified PPARαactivation as a dual senolytic / autophagy enhancing strategy by using
a human chondrocyte cell-based phenotypic screening assay. Senes-
cence was induced by treatment with SASP factor IL-6 [53], increasing
SA-β-Gal activity and p21 expression, while decreasing autophagic
flux and inducing the mTOR signalling pathway. Paracrine exposure of
chondrocytes to IL-6 likely resembles some of the early ageing and car-
tilage degeneration signalling events which were considered key in OA
development. These results also suggest an interesting homeostatic
imbalance, whereby IL-6-induced inflammation and senescence is ac-
companied by decreased autophagy in chondrocytes. This observation
Fig. 10. PPARα is downregulated in blood and cartilage from OA patients. a. Relative expression of PPARα in blood from non-OA and OA patients from OA cohort, PROCOAC. Values are
mean ± SEM of n = 25 non-OA patients and n = 30 Knee OA patients, *p b .001 vs. non-OA, two-tailed unpaired Student's t-test. b. Human Normal and OA cartilage was analysed by
immunohistochemistry for PPARα. Representative images of normal and OA cartilage stained with PPARα. Scale bar, 10 μm. c, Quantitative analysis of PPARα-positive cells. Values are
the mean ± SEM of n = 5 human donors per group. *p b .05 vs. normal, two-tailed unpaired Student's t-test. d, Longitudinal analysis (with treatment* time interaction) of WOMAC
subcategories and fibrates use.
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creased autophagy that can promote cartilage disease.
Our cell-based screening assay yielded a number of drugs with dif-
ferent mechanism of actions potentially interacting with OA pathogen-
esis pathways. A number of ion channels and pumps disruptors were
identified. Since hormones, growth factors, cytokines, and eicosanoids
are critical signals for mainteinance of chondrocyte homeostasis, the
PPARα nuclear receptor was of prime interest because is an established
modulator of lipid metabolism and its role in the inflammatory mecha-
nism can explain the positive impact in cartilage homeostasis [54,55].Indeed, it has been demonstrated that PPARγ has a protective role in ar-
ticular cartilage. Cartilage-specific PPARγ deficient mice showed in-
creased apoptosis as well as production of inflammatory and catabolic
factors, and a decreased expression of anabolic factors, overall resulting
in accelerated OA [56,57]. Here, we have demonstrated that the PPARα
agonist fenofibrate (FN) significantly reduced chondrocyte senescence
and induced autophagic flux significantly, indicating a partial reversion
of the chondrocyte age-related phenotype.
Our results demonstrate that PPARα ligands selectively eliminate se-
nescent chondrocytes via cell death through apoptosis [4]. In addition,
604 U. Nogueira-Recalde et al. / EBioMedicine 45 (2019) 588–605PPARα agonists induced autophagic flux,mediated by a related increase
in cell homeostasis markers, such as LC3 and FoxO1. Moreover, treating
OA and ageing chondrocytes with fenofibrate results in abrogation of
the active, phosphorylated form of themTOR effector S6 Ribosomal Pro-
tein. Senescent cells are prone to anti-apoptotic signals and show irre-
versible proliferative arrest [58]. Downregulation of this proliferation
pathway may contribute to the senolytic activity of PPARα ligands,
however, further work using PPARα ligands is required to establish
how nuclear receptor signalling remodels cartilage metabolism and
the full range of signalling it regulates.
To investigate the relevance of PPARα as a therapeutic target, we ex-
plore whether its genetic deletion could affect critical chondrocyte sur-
vivalmechanisms.We found that PPARα deficient human chondrocytes
were susceptible to senescence, increased expression of inflammation
mediators and to changes in homeostasis by a reduction of FoxO1 ex-
pression and an increase in LC3, which might act as a regulator of lipid
signals influencing homeostasis. These results highlight the importance
of PPARα in maintenance of chondrocyte homeostasis.
Since PPARα regulates peroxisomal and mitochondrial fatty acid β-
oxidation [59], the effect of PPARα agonists in human chondrocytes
also was evaluated. The results showed an increase in expression of
CPT1A expression, a target gene of PPARα [60], suggesting that these li-
gands regulate mitochondrial fatty acid β-oxidation in human
chondrocytes. These results are consistent with a positive remodelling
of cartilage metabolism that protects against ageing and disease signals.
PPARα was found to be downregulated in spontaneous ageing-
related and surgically induced OA mouse models, as well as in blood
and cartilage from patients with knee OA, indicating an intrinsic OA-
related PPARα defect. Importantly, pharmacological activation of
PPARα by fibrate treatment in human OA patients was associated
with a significant decrease in progressive disability and a trend towards
a decrease in knee pain. Therewere fewer joint replacement surgeries in
patients taking fibrates. These findings are in line with an open label
study performed on patients with erosive hand OA where FN use for
12 weeks was associated with significant improvements in the Cochin
hand functional disability scale [61]. In another exploratory study car-
ried out through the OAI database, neither reduced radiographic pro-
gression nor reduction in worsening of pain in participants taking
fibrates were detected. The authors did not assess the effects of fibrates
on disability and used a prevalent user design (i.e. included participants
whousedfibrates at baseline) [62] thatmay be associatedwith bias [63]
andmay account for the non-detection of fibrate effect on pain. It is dif-
ficult to interpret the dissociation of fibrate effects on disability and pain
found in this analysis as pain and functional limitation in knee OA are
closely related [64]. As anxiety has been shown to be one of the determi-
nants of functioning in knee OA [65], one of the explanations of the re-
duction in disability found in the present study may be the observed
emerging anxiolytic effects of PPARα agonism [66]. On the other hand,
the lack of association between fibrate use and pain reduction may be
due to absence of analgesic properties of PPARα agonists or may be
due to reduced statistical power caused by small sample size.
These clinical findings support the hypothesis that fibrates may im-
prove joint function in human OA patients and encourage further pro-
spective and conclusive studies to demonstrate the value of fibrates as
disease modifying OA therapy.
In conclusion, regulation of lipid metabolism by PPARα can be con-
sidered as a potential therapeutic target for OA.
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